We have located links that may give you full text access.
Cdk6 coordinates Jak2 V617F mutant MPN via NFκB and apoptotic networks.
Blood 2019 January 12
Over 80% of patients with myeloproliferative neoplasms (MPNs) harbour the acquired somatic Jak2V617F mutation. JAK inhibition is not curative and fails to induce a persistent response in most patients, illustrating the need for the development of novel therapeutic approaches. We describe a critical role for CDK6 in MPN evolution. The absence of Cdk6 ameliorates clinical symptoms and prolongs survival. The CDK6 protein interferes with three hallmarks of disease: besides regulating malignant stem cell quiescence, it promotes NFκB signaling and contributes to cytokine production while inhibiting apoptosis. The effects are not mirrored by palbociclib, showing that the functions of CDK6 in MPN pathogenesis are largely kinase-independent. Our findings thus provide a rationale for targeting CDK6 in MPN.
Full text links
Related Resources
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app